Chardan Capital reaffirmed their buy rating on shares of Silence Therapeutics (NASDAQ:SLN – Free Report) in a research note issued to investors on Friday, Benzinga reports. The firm currently has a $42.00 price target on the stock. A number of other analysts have also commented on SLN. BMO Capital Markets initiated coverage on Silence Therapeutics […]

Related Keywords

, Janus Henderson Group , Vivo Capital , Parkman Healthcare Partners , Morgan Stanley , Nasdaq , Sg Americas Securities , Chardan Capital , Silence Therapeutics , Free Report , Get Free Report , Healthcare Partners , Oligonucleotide Discovery , Silence Therapeutics Daily ,